219 related articles for article (PubMed ID: 31514197)
21. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Hehlmann R; Cortes JE; Zyczynski T; Gambacorti-Passerini C; Goldberg SL; Mauro MJ; Michallet M; Simonsson B; Williams LA; Gajavelli S; DeGutis I; Sen GP; Paquette RL
Am J Hematol; 2019 Jan; 94(1):46-54. PubMed ID: 30290003
[TBL] [Abstract][Full Text] [Related]
23. The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
Soysal T; Eskazan AE; Serin I; Sadri S; Keskin D; Ozgur Yurttas N; Berk S; Erdogan Ozunal I; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Ozbek U; Aydin Y
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e377-e384. PubMed ID: 31088736
[TBL] [Abstract][Full Text] [Related]
24. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
[TBL] [Abstract][Full Text] [Related]
26. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
28. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.
Haznedaroglu IC
Expert Opin Pharmacother; 2013 Oct; 14(15):2005-10. PubMed ID: 23984805
[TBL] [Abstract][Full Text] [Related]
29. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Castagnetti F; Di Raimondo F; De Vivo A; Spitaleri A; Gugliotta G; Fabbiano F; Capodanno I; Mannina D; Salvucci M; Antolino A; Marasca R; Musso M; Crugnola M; Impera S; Trabacchi E; Musolino C; Cavazzini F; Mineo G; Tosi P; Tomaselli C; Rizzo M; Siragusa S; Fogli M; Ragionieri R; Zironi A; Soverini S; Martinelli G; Cavo M; Vigneri P; Stagno F; Rosti G; Baccarani M
Am J Hematol; 2017 Jan; 92(1):82-87. PubMed ID: 27770583
[TBL] [Abstract][Full Text] [Related]
30. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
31. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
32. Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
Gugliotta G; Castagnetti F; Breccia M; Gozzini A; Usala E; Carella AM; Rege-Cambrin G; Martino B; Abruzzese E; Albano F; Stagno F; Luciano L; D'Adda M; Bocchia M; Cavazzini F; Tiribelli M; Lunghi M; Pia Falcone A; Musolino C; Levato L; Venturi C; Soverini S; Cavo M; Alimena G; Pane F; Martinelli G; Saglio G; Rosti G; Baccarani M;
Am J Hematol; 2016 Jun; 91(6):617-22. PubMed ID: 26971721
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX
Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142
[TBL] [Abstract][Full Text] [Related]
34. High
Vigneri P; Stagno F; Stella S; Cupri A; Forte S; Massimino M; Antolino A; Siragusa S; Mannina D; Impera SS; Musolino C; Malato A; Mineo G; Tomaselli C; Murgano P; Musso M; Morabito F; Molica S; Martino B; Manzella L; Müller MC; Hochhaus A; Raimondo FD
Clin Cancer Res; 2017 Dec; 23(23):7189-7198. PubMed ID: 28928163
[No Abstract] [Full Text] [Related]
35. Update on emerging treatments for chronic myeloid leukemia.
Fava C; Morotti A; Dogliotti I; Saglio G; Rege-Cambrin G
Expert Opin Emerg Drugs; 2015 Jun; 20(2):183-96. PubMed ID: 25826695
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
37. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Jabbour E; Kantarjian HM; O'Brien S; Shan J; Quintás-Cardama A; Garcia-Manero G; Rios MB; Cortes JE
J Clin Oncol; 2011 Nov; 29(32):4260-5. PubMed ID: 21990394
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa S; Ueda Y; Usuki K; Kobayashi H; Kondo E; Doki N; Nakao T; Kanda Y; Kosugi N; Kosugi H; Kumagai T; Harada H; Shikami M; Maeda Y; Sakura T; Inokuchi K; Saito A; Nawa Y; Ogasawara M; Nishida J; Kondo T; Yoshida C; Kuroda H; Tabe Y; Maeda Y; Imajo K; Kojima K; Morita S; Komukai S; Kawaguchi A; Sakamoto J; Kimura S
Int J Clin Oncol; 2019 Apr; 24(4):445-453. PubMed ID: 30421023
[TBL] [Abstract][Full Text] [Related]
39. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
40. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]